Seeking Alpha

Penn Bioinvestor » Comments » LLY

  • ADA Meeting 2009: Novel Diabetes Therapies Presented  [View article]
    You forgot an important drug candidate from Incyte:
    Results Presented at the ADA 69th Scientific Sessions Demonstrate that INCB13739, Incyte’s Oral 11beta-HSD1 Inhibitor, Significantly Improves Glycemic Control, Insulin Sensitivity and Total Cholesterol in Patients with Type 2 Diabetes
    Jun 24 19:19 pm |Rating: +1 0 |Link to Comment
More on LLY by Penn Bioinvestor
Comments by Ticker
Penn Bioinvestor's
Comments Stats
52 comments
Rating: 51 (87 - 36 )